Adicet Bio(US:ACET)2025-11-05 21:02Financial Performance - Adicet Bio reported a net loss of $26.9 million for Q3 2025, a decrease from a net loss of $30.5 million in Q3 2024, resulting in a net loss per share of $0.29 compared to $0.34 in the prior year[9]. - Research and Development (R&D) expenses were $22.9 million for Q3 2025, down from $26.3 million in Q3 2024, primarily due to reductions in payroll and personnel expenses[9]. - General and Administrative (G&A) expenses decreased to $5.1 million in Q3 2025 from $6.9 million in Q3 2024, mainly due to lower payroll and personnel costs[9]. - Adicet's accumulated deficit reached $584.2 million as of September 30, 2025, compared to $497.9 million at the end of 2024[15]. Cash Position - Cash, cash equivalents, and short-term investments totaled $103.1 million as of September 30, 2025, down from $176.3 million at the end of 2024, with additional funding expected to extend the cash runway into the second half of 2027[9][8]. - The company raised $74.8 million in net proceeds from a registered direct offering in October 2025, enhancing its financial position[8]. Clinical Trials and Regulatory Plans - Positive preliminary data from the Phase 1 trial of ADI-001 showed rapid and sustained reductions in SLEDAI-2K scores and improved renal function in all patients with lupus nephritis[4]. - The company plans to request a meeting with the FDA in Q1 2026 to discuss the design of a potentially pivotal trial for ADI-001, with study initiation anticipated in Q2 2026[1]. - Adicet is actively enrolling patients in the Phase 1 study of ADI-001 for treatment-refractory rheumatoid arthritis, evaluating the potential to reduce the need for conditioning[6]. - A regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer is planned for Q1 2026, with initial clinical data expected in the second half of 2026[3][7].